Reuters logo
BRIEF-Array Biopharma reports Phase 3 BEACON CRC Safety Results, initial clinical activity
September 8, 2017 / 5:14 PM / 17 days ago

BRIEF-Array Biopharma reports Phase 3 BEACON CRC Safety Results, initial clinical activity

Sept 8 (Reuters) - Array Biopharma Inc

* Phase 3 beacon crc safety lead-in results in braf-mutant colorectal cancer presented at european society for medical oncology congress

* says ‍study was generally well-tolerated with “attractive” safety profile​

* Says ‍in safety lead-in, triplet combination was generally well-tolerated​

* Says in study ‍three patients discontinued treatment due to adverse events​ with only one considered related to treatment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below